S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

HTG Molecular Diagnostics Stock Price, News & Analysis (NASDAQ:HTGM)

$0.80
+0.02 (+2.56 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$0.77
Now: $0.80
$0.84
50-Day Range
$0.61
MA: $0.78
$0.88
52-Week Range
$0.60
Now: $0.80
$4.27
Volume256,855 shs
Average Volume290,888 shs
Market Capitalization$43.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
HTG Molecular Diagnostics, Inc a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTGM
CUSIPN/A
Phone877-289-2615

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.50 million
Book Value$0.74 per share

Profitability

Net Income$-16,450,000.00

Miscellaneous

Employees107
Market Cap$43.35 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.


HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics Inc (NASDAQ:HTGM) announced its quarterly earnings data on Tuesday, August, 6th. The medical research company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.02. The medical research company earned $5.80 million during the quarter, compared to analyst estimates of $5.54 million. HTG Molecular Diagnostics had a negative net margin of 79.96% and a negative return on equity of 95.77%. View HTG Molecular Diagnostics' Earnings History.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for HTG Molecular Diagnostics.

What guidance has HTG Molecular Diagnostics issued on next quarter's earnings?

HTG Molecular Diagnostics issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23-26 million, compared to the consensus revenue estimate of $24.96 million.

What price target have analysts set for HTGM?

4 brokerages have issued twelve-month target prices for HTG Molecular Diagnostics' stock. Their predictions range from $1.50 to $6.00. On average, they anticipate HTG Molecular Diagnostics' stock price to reach $3.63 in the next year. This suggests a possible upside of 353.1% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics.

What is the consensus analysts' recommendation for HTG Molecular Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics.

What are Wall Street analysts saying about HTG Molecular Diagnostics stock?

Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock:
  • 1. Canaccord Genuity analysts commented, "We were pleased to host newer HTG CEO John Lubniewski and CFO Conference last week in Boston. Our key takeaways: (1) HTG is making a bigger push to develop and launch novel diagnostic test launches in breast and lung cancer; (2) HTG is not getting any credit in its stock price for strong 80%+ Y/Y growth in its base RUO profiling business; and (3) HTG has taken adverse lumps" because they haven’t converted a CDx yet (yet they have over 70 active global pharma programs). We reiterate our BUY rating and trim our PT to $3, which we would be inclined to raise should HTG hit" on one of its pharma collaborations. EdgeSeq Breast Total Lung." (8/13/2019)
  • 2. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (8/10/2019)
  • 3. HC Wainwright analysts commented, "Our 12-month price target is based on an estimated market value of the firm at $237M. This includes an asset value at $247M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate, excluding $10M debt." (6/18/2019)
  • 4. Cantor Fitzgerald analysts commented, "We reaffirm our OW rating and think HTG’s EdgeSeq offers an attractive workflow solution that addresses key challenges in many existing molecular profiling technologies on the market. We view RNA-based panels as well-positioned to capitalize on trends in biomarker development, including faster turnaround time, lower sample-volume requirement, and next-gen sequencing (NGS)- based testing. We think shares of HTG will be rewarded with consistent product and service revenue acceleration along with a demonstrated growing pipeline of exclusive revenue-generating PDPs." (2/20/2019)

Has HTG Molecular Diagnostics been receiving favorable news coverage?

Press coverage about HTGM stock has trended neutral on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. HTG Molecular Diagnostics earned a news impact score of 0.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for HTG Molecular Diagnostics.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,770,000 shares, an increase of 6.5% from the August 30th total of 2,600,000 shares. Based on an average trading volume of 313,900 shares, the short-interest ratio is presently 8.8 days. Approximately 19.2% of the company's stock are short sold. View HTG Molecular Diagnostics' Current Options Chain.

Who are some of HTG Molecular Diagnostics' key competitors?

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA), FleetMatics Group (FLTX), Proteostasis Therapeutics (PTI), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP), Resonant (RESN), Verastem (VSTM), Neovasc (NVCN) and Zosano Pharma (ZSAN).

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the folowing people:
  • Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)
  • Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)
  • Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)
  • Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)
  • Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (4.34%). View Institutional Ownership Trends for HTG Molecular Diagnostics.

Which institutional investors are buying HTG Molecular Diagnostics stock?

HTGM stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for HTG Molecular Diagnostics.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $0.80.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $43.35 million and generates $21.50 million in revenue each year. The medical research company earns $-16,450,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe.View Additional Information About HTG Molecular Diagnostics.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is http://www.htgmolecular.com/.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.


MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  506
MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel